At a glance
- Originator UCB
- Class Antihyperlipidaemics; Antithrombotics
- Mechanism of Action Cyclic nucleotide phosphodiesterase inhibitors; Platelet aggregation inhibitors; Thromboxane receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Atherosclerosis; Thrombosis
Most Recent Events
- 13 Apr 1995 Discontinued-Preclinical for Atherosclerosis in Germany (Unknown route)
- 13 Apr 1995 Discontinued-Preclinical for Thrombosis in Germany (Unknown route)